Tenapanor as Add-on Treatment for Hyperphosphatemia in Dialysis Patients: Enough Bang for the Buck?
dc.contributor.author | Wish, Jay B. | |
dc.contributor.department | Medicine, School of Medicine | |
dc.date.accessioned | 2024-03-22T11:53:38Z | |
dc.date.available | 2024-03-22T11:53:38Z | |
dc.date.issued | 2023-10-06 | |
dc.eprint.version | Final published version | |
dc.identifier.citation | Wish JB. Tenapanor as Add-on Treatment for Hyperphosphatemia in Dialysis Patients: Enough Bang for the Buck?. Kidney Int Rep. 2023;8(11):2194-2197. Published 2023 Oct 6. doi:10.1016/j.ekir.2023.10.001 | |
dc.identifier.uri | https://hdl.handle.net/1805/39419 | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | |
dc.relation.isversionof | 10.1016/j.ekir.2023.10.001 | |
dc.relation.journal | Kidney International Reports | |
dc.rights | Attribution 4.0 International | en |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.source | PMC | |
dc.subject | Hyperphosphatemia | |
dc.subject | Dialysis | |
dc.subject | Chronic kidney disease | |
dc.subject | Bone disorder | |
dc.title | Tenapanor as Add-on Treatment for Hyperphosphatemia in Dialysis Patients: Enough Bang for the Buck? | |
dc.type | Article |